- ACADIA Pharmaceuticals (NASDAQ:ACAD) Q1 results ($M): NUPLAZID sales: 63.0 (+28.8%).
- Net loss: (85.3) (-57.1%); loss/share: (0.59) (-31.8%).
- 2019 guidance: NUPLAZID sales: $280M - 300M.
- Previously: ACADIA Pharma misses by $0.07, beats on revenue (May 1)
Acadia Q1 Nuplazid sales up 29%
Recommended For You
About ACAD Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ACAD | - | - |
ACADIA Pharmaceuticals Inc. |